Kailera Therapeutics, Inc.
corporate_fare Company Profile
Kailera Therapeutics, Inc. (NASDAQ:KLRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for KLRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for KLRA spans 10-Q, 8-K, SCHEDULE 13D, 4.
Recent high-impact activity:
- Kailera Posts $95.7M Q3 Loss as Obesity Pipeline Hits Full Enrollment
- Kailera's Tri-Agonist Shows Up to 16% Weight Loss in Phase 1
- Kailera Q2 2026: Net Loss Widens to $111.3M, Cash Runway Extended to Mid-2028
- Kailera Reports Q2 2026 Results: $1.17B Cash, Phase 3 Obesity Trials on Track
- Kailera's Oral GLP-1 KAI-7535 Achieves Up to 10.9% Weight Loss in Phase 3 Obesity Trial
Short Interest & Short Volume
7.85 days to coverFINRA reported short interest of 8,163,674 shares in KLRA as of the October 30, 2026 settlement, a 1.8% decrease from the prior period — about 7.8 days to cover at its recent average daily volume. On November 20, 2026, 60.0% of KLRA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.